[Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005379
German
Original Title: Trifluridin/Tipiracil (Kolorektalkarzinom; Kombination mit Bevacizumab)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a23-85.html
Year Published: 2023
URL for published report: https://www.iqwig.de/download/a23-85_trifluridin-tipiracil_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://dx.doi.org/10.60584/A23-85
MeSH Terms
  • Colorectal Neoplasms
  • Bevacizumab
  • Trifluridine
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents, Immunological
  • Pyrrolidines
Keywords
  • Trifluridine
  • Tipiracil
  • Bevacizumab
  • Colorectal Neoplasms
  • Benefit Assessment
  • NCT04737187
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.